Multiple Sclerosis Journal

Article	Citations
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition	1009
COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021	180
COVID-19 in multiple sclerosis: The Dutch experience	71
Multiple sclerosis management during the COVID-19 pandemic	60
A smartphone sensor-based digital outcome assessment of multiple sclerosis	54
COVID-19 in people with multiple sclerosis: A global data sharing initiative	48
Aggressive multiple sclerosis (1): Towards a definition of the phenotype	41
In vivo imaging of chronic active lesions in multiple sclerosis	39
Vaccinations in patients with multiple sclerosis: A Delphi consensus statement	39
MSVirtual 2020 – Poster Abstracts	38
Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres	38
Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients	37
Synaptic and complement markers in extracellular vesicles in multiple sclerosis	36
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study	36
Macular ganglion cell–inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis	35
Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression	35
Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms	34
Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network	34
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension	33
The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: A Mendelian randomization mediation analysis	32
MOG-IgG1 and co-existence of neuronal autoantibodies	32
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MO	31
Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient	31
Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review	31
Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results	31

Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression	31
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies	30
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II	30
Childhood obesity and multiple sclerosis: A Mendelian randomization study	30
Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis	30
The emerging role of artificial intelligence in multiple sclerosis imaging	30
Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis	29
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years	29
A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis	29
Expansion of chronic lesions is linked to disease progression in relapsing–remitting multiple sclerosis patients	29
Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis	29
Exercise training and cognitive performance in persons with multiple sclerosis: A systematic review and multilevel meta-analysis of clinical trials	28
Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic	28
ADEM after ChAdOx1 nCoV-19 vaccine: A case report	28
Cortical lesion hotspots and association of subpial lesions with disability in multiple sclerosis	28
COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment	27
COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments	26
Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity	26
Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS	26
Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD	25
Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis	25
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study	25
A validation study for remote testing of cognitive function in multiple sclerosis	25
Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation	25
Defective CD19+CD24hiCD38hi transitional B-cell function in patients with relapsing-remitting MS	25
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study	25
Frailty in ageing persons with multiple sclerosis	24
Acute disseminated encephalomyelitis in children and adults: A focused review emphasizing new developments	24
Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey	24
Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with ‘aggressive’ multiple sclerosis	24
The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement	24
Keeping standards of multiple sclerosis care through the COVID-19 pandemic	24
Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology	24
ECTRIMS 2021 – ePoster	24
Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders	24
High-intensity interval training reduces neutrophil-to-lymphocyte ratio in persons with multiple sclerosis during inpatient rehabilitation	24
Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis	24
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study	24
Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy	23
Serum neurofilament light in MS: The first true blood-based biomarker?	23
COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence?	23
Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry	22
Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis	22
Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database	22
Optic chiasm involvement in AQP-4 antibody–positive NMO and MOG antibody–associated disorder	22
ACTRIMS Forum 2023 - Poster Presentations	22
Serum ceramide levels are altered in multiple sclerosis	22
Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab	21
Time matters: Early-phase multiple sclerosis is accompanied by considerable impairments across multiple domains	21
Deep learning segmentation of gadolinium-enhancing lesions in multiple sclerosis	21

Feelings of depression, pain and walking difficulties have the largest impact on the quality of life of people with multiple sclerosis, irrespective of clinical phenotype	21
Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring	21
Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis	21
Mediterranean diet is linked to less objective disability in multiple sclerosis	21
Aggressive multiple sclerosis (2): Treatment	21
A novel in-home digital treatment to improve processing speed in people with multiple sclerosis: A pilot study	20
Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohort	20
The cerebellum and its network: Disrupted static and dynamic functional connectivity patterns and cognitive impairment in multiple sclerosis	20
Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy	20
Classifying multiple sclerosis patients on the basis of SDMT performance using machine learning	20
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors	20
The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia	20
Structural constraints of functional connectivity drive cognitive impairment in the early stages of multiple sclerosis	20
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years	19
De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis	19
Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome	19
Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis	19
MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination	19
Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses	19
Mapping white matter damage distribution in neuromyelitis optica spectrum disorders with a multimodal MRI approach	19
Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis	19
Gut commensals, dysbiosis, and immune response imbalance in the pathogenesis of multiple sclerosis	19
Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations	18
Patient-reported financial toxicity in multiple sclerosis: Predictors and association with care non-adherence	18
Atlas of MS 2020: Informing global policy change	18
COVID-19 vaccine hesitancy in multiple sclerosis: A cross-sectional survey	18
Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS	18
The timed 25-foot walk in a large cohort of multiple sclerosis patients	18
Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis	18
Prevalence, co-occurrence, and trajectories of pain, fatigue, depression, and anxiety in the year following multiple sclerosis diagnosis	18
Efficacy of high-intensity aerobic exercise on cognitive performance in people with multiple sclerosis: A randomized controlled trial	17
Extended dosing of monoclonal antibodies in multiple sclerosis	17
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focuse	17
Performance validity in outpatients with multiple sclerosis and cognitive complaints	17
The central vein sign in multiple sclerosis patients with vascular comorbidities	17
Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES)	17
Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica	17
Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder	16
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial	16
Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study	16
Cladribine transfer into human milk: A case report	16
Staging and stratifying cognitive dysfunction in multiple sclerosis	16
Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis	16
Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI	16
Home-based Pilates for symptoms of anxiety, depression and fatigue among persons with multiple sclerosis: An 8-week randomized controlled trial	16
Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSD	16
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analys	16
Increased functional sensorimotor network efficiency relates to disability in multiple sclerosis	16
ECTRIMS 2022 – Poster	16
Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosis	16
Characterization of thalamic lesions and their correlates in multiple sclerosis by ultra-high-field MRI	15
Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis	15
Ethical use of off-label disease-modifying therapies for multiple sclerosis	15
Acute and chronic synaptic pathology in multiple sclerosis gray matter	15
Real-world disability improvement in patients with relapsing–remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program	15
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies	15
Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis	15
Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation	15
Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review	15
Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis	14
School performance, psychiatric comorbidity, and healthcare utilization in pediatric multiple sclerosis: A nationwide population-based observational study	14
Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis	14
Leptomeningeal enhancement on post-contrast FLAIR images for early diagnosis of Susac syndrome	14
The frequency and characteristics of multiple sclerosis misdiagnosis in Latin America: A referral center study in Buenos Aires, Argentina	14
What does first-line therapy mean for paediatric multiple sclerosis in the current era?	14
Identification of regulatory T cell molecules associated with severity of multiple sclerosis	14
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial	14
Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study	14
Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis	14
Longitudinal clinical study of patients with iron rim lesions in multiple sclerosis	14
Accurate classification of secondary progression in multiple sclerosis using a decision tree	14
Brain structural and functional alterations in MOG antibody disease	13
Switching from natalizumab to ocrelizumab in patients with multiple sclerosis	13
Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement	13
Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care	13
Methylome and transcriptome signature of bronchoalveolar cells from multiple sclerosis patients in relation to smoking	13
MRI correlates of clinical disability and hand-motor performance in multiple sclerosis phenotypes	13
The SDMT is not information processing speed	13
Measurement of white matter fiber-bundle cross-section in multiple sclerosis using diffusion-weighted imaging	13
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis	13

Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening	13
Resting-state functional connectivity of anterior and posterior cerebellar lobes is altered in multiple sclerosis	13
Cortical axonal loss is associated with both gray matter demyelination and white matter tract pathology in progressive multiple sclerosis: Evidence from a combined MRI-histopathology study	13
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data	13
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis	13
Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders	13
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy	13
Paramagnetic rim lesions are associated with pathogenic CSF profiles and worse clinical status in multiple sclerosis: A retrospective cross-sectional study	13
Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis	13
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions	13
Effectiveness of the transcutaneous tibial nerve stimulation and pelvic floor muscle training with biofeedback in women with multiple sclerosis for the management of overactive bladder	13
Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry	12
Artificial double inversion recovery images for (juxta)cortical lesion visualization in multiple sclerosis	12
Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis	12
Inhibitory synaptic loss drives network changes in multiple sclerosis: An ex vivo to in silico translational study	12
Body mass index as a predictor of MS activity and progression among participants in BENEFIT	12
ECTRIMS 2022 – ePoster	12
Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients	12
Characterization of multiple sclerosis neuroinflammation and neurodegeneration with relaxation and diffusion basis spectrum imaging	12
Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?	12
PRF1 mutation alters immune system activation, inflammation, and risk of autoimmunity	11
Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis	11
Youth with multiple sclerosis have low levels of fitness	11
Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial	11
Conscientiousness and deterioration in employment status in multiple sclerosis over 3 years	11
Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States	11
Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society	11
Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study	11
Productivity loss among people with early multiple sclerosis: A Canadian study	11
Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy)	11
Predictive value of optical coherence tomography, multifocal visual evoked potentials, and full-field visual evoked potentials of the fellow, non-symptomatic eye for subsequent multiple sclerosis deve	11
Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis	11
Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study	11
The effects of supervised versus home Pilates-based core stability training on lower extremity muscle strength and postural sway in people with multiple sclerosis	11
Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS	11
Cumulative effects of therapies on disability in relapsing multiple sclerosis	11
Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance	11
Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis	11
A proposed new taxonomy of cognitive phenotypes in multiple sclerosis: The International Classification of Cognitive Disorders in MS (IC-CoDiMS)	11
Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case–control study of the UK MS Register	11
Changes in multiple sclerosis symptoms are associated with changes in work productivity of people living with multiple sclerosis	11
EDSS 0 is not normal: Multiple sclerosis disease burden below the clinical threshold	11
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD	11
Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria	11
Exercise and the brain in multiple sclerosis	10
Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?	10
Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis	10
High Prudent diet factor score predicts lower relapse hazard in early multiple sclerosis	10
Clinical perspective on pain in multiple sclerosis	10
Physical exercise in multiple sclerosis is not just a symptomatic therapy: It has a disease-modifying effect—Yes	10
Pathways to cures for multiple sclerosis: A research roadmap	10
Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation	10
Patient reported outcomes and performance metrics at diagnosis of secondary progressive multiple sclerosis	10
Hypertension and hypertension severity in Hispanics/Latinx with MS	10
Altered brain network function during attention-modulated visual processing in multiple sclerosis	10
MS, pregnancy and COVID-19	10
Slowly expanding lesions are a marker of progressive MS – Yes	10
Exposure to natalizumab during pregnancy and lactation is safe – Yes	10
Brain MRI activity during the year before pregnancy can predict post-partum clinical relapses	10
Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD	9
Changes in prognosis of the Danish multiple sclerosis population over time	9
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry	9
Visual field loss and structure–function relationships in optic neuritis associated with myelin oligodendrocyte glycoprotein antibody	9
Gene–environment interactions increase the risk of pediatric-onset multiple sclerosis associated with ozone pollution	9
Pregnancy in women with multiple sclerosis in France from 2010 to 2015: Incidence, outcomes, and exposure to disease-modifying therapies	9
Epilepsy as a predictor of disease progression in multiple sclerosis	9
Comparison of MOG and AQP4 antibody seroprevalence in Korean adults with inflammatory demyelinating CNS diseases	9
CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event	9
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis	9
Fatal underhanded chronic enterovirus infection associated with anti-CD20 monotherapy for central nervous system demyelinating disease	9
T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis: No	9
Multi-layer analysis of quantitative 7 T magnetic resonance imaging in the cortex of multiple sclerosis patients reveals pathology associated with disability	9
Long-term course and morphological MRI correlates of cognitive function in multiple sclerosis	9
A randomized trial predicting response to cognitive rehabilitation in multiple sclerosis: Is there a window of opportunity?	9
BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS	9
Depression and cognitive function in early multiple sclerosis: Multitasking is more sensitive than traditional assessments	9
An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis	9
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica	9
Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis	9
Cardiorespiratory fitness and free-living physical activity are not associated with cognition in persons with progressive multiple sclerosis: Baseline analyses from the CogEx study	9
Slowly expanding lesions are a marker of progressive MS – No	9
Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis	9
COVID-19 will change MS care forever – No	8
Progressive multifocal leukoencephalopathy on dimethyl fumarate with preserved lymphocyte count but deep T-cells exhaustion	8
High prevalence of comorbidities at diagnosis in immigrants with multiple sclerosis	8
A possible case of serum sickness after ocrelizumab infusion	8
Depression and multiple sclerosis: A bidirectional Mendelian randomisation study	8
Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis	8
Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate	8
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs	8
Dietary factors in experimental autoimmune encephalomyelitis and multiple sclerosis: A comprehensive review	8
Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies	8
A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database	8
Depression in multiple sclerosis across the adult lifespan	8
Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability	8